Reactogenicity and Peak Anti-RBD-S1 IgG Concentrations in Individuals with No Prior COVID-19 Infection Vaccinated with Different SARS-CoV-2 Vaccines

Abstract Objective To investigate the association of immune response with vaccination adverse effects at peak anti–receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria. Methods Anti-RBDS1 IgG concentrations after vaccination were dete...

Full description

Saved in:
Bibliographic Details
Published in:Laboratory medicine 2024-03, Vol.55 (2), p.162-168
Main Authors: Milevoj Kopcinovic, Lara, Unic, Adriana, Nikolac Gabaj, Nora, Miler, Marijana, Vrtaric, Alen, Bozovic, Marija, Stefanovic, Mario
Format: Article
Language:English
Subjects:
2019-nCoV Vaccine mRNA-1273
Adult
BNT162 Vaccine
ChAdOx1 nCoV-19
COVID-19 - prevention & control
COVID-19 Vaccines - adverse effects
Humans
Immunoglobulin G
SARS-CoV-2
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Objective To investigate the association of immune response with vaccination adverse effects at peak anti–receptor-binding domain spike subunit 1 (anti-RBDS1) IgG after full vaccination with Comirnaty, Spikevax, or Vaxzevria. Methods Anti-RBDS1 IgG concentrations after vaccination were determined in healthy adults vaccinated with the Comirnaty, Spikevax, and Vaxzevria vaccines. The association of reactogenicity and peak antibody response after vaccination was tested. Results Anti-RBDS1 IgG values were significantly higher in the Comirnaty and Spikevax group, compared with the Vaxzevria group (P < .001). Fever and muscle pain were found to be significant independent predictors of peak anti-RBDS1 IgG in the Comirnaty and Spikevax groups (P = .03 and P = .02, respectively). The multivariate model, adjusted for covariates, showed that no association between reactogenicity and peak antibody concentrations was found in the Comirnaty, Spikevax, and Vaxzevria groups. Conclusions No association between reactogenicity and peak anti-RBDS1 IgG after vaccination with the Comirnaty, Spikevax, and Vaxzevria vaccine was found.
ISSN:0007-5027
1943-7730
DOI:10.1093/labmed/lmad044